Gender Difference in Hematological Toxicity Among Lung Cancer Patients Receiving Amrubicin Monotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Gender Difference in Hematological Toxicity Among Lung Cancer Patients Receiving Amrubicin Monotherapy

Published:2012-10-17 Issue:12 Volume:42 Page:1187-1191
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:Japanese Journal of Clinical Oncology

Author:

Makihara R. A.,Makino Y.,Yamamoto N.,Yokote N.,Nokihara H.,Sekine I.,Ohe Y.,Tamura T.,Yamamoto H.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/42/12/1187/5105387/hys170.pdf

Reference13 articles.

1. Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline.

2. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study

3. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

4. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study

5. Pharmacokinetics of Amrubicin and Its Active Metabolite Amrubicinol in Lung Cancer Patients

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sex Differences in Hazard Ratio During Drug Treatment of Non–small-cell Lung Cancer in Major Clinical Trials: A Focused Data Review and Meta-analysis;Clinical Therapeutics;2017-01

2. Population Pharmacodynamic Model for Bayesian Prediction of Myelosuppression Profiles Based on Routine Clinical Data after Gemcitabine and Carboplatin Treatment;Pharmacology;2016

3. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?;Radiation Oncology;2015-08-04

4. Risk Factors of Severe Neutropenia during Cancer Chemotherapy;Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences);2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3